Skip to content

Study · Non-randomized trial · n = 10 · 2021

2 results

Novel function of adrenocorticotropic hormone in the stimulation of vascular endothelial growth factor release in healthy children and adolescents: a proof-of-concept study.

Heksch R, Bowden S, Hoffman R

Annals of pediatric endocrinology & metabolism3 Feb 2021Cited by 1 (Europe PMC)

PMID33541031 (opens in a new tab)PMCIDPMC8026337 (opens in a new tab)DOI10.6065/apem.2040110.055 (opens in a new tab)PepBankPUB-33541031
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In healthy children and adolescents, peak plasma VEGF increased versus baseline after high-dose cosyntropin following a low dose (P=0.042).

    In plain wordsIn healthy children and adolescents, peak VEGF increased versus baseline after high-dose cosyntropin following a low dose.

    Peptide
    Cosyntropin
    Outcome
    IncreasePeak plasma VEGF after high dose
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    250 μgAs given in this study (human).

    Source sentences

    Summary
    Peak plasma VEGF levels significantly increased after high-dose cosyntropin compared with baseline (P=0.042).
    2 context sentences
    Summary · context
    An Institutional Review Board-approved prospective study of 10 healthy subjects, ages 9-17, was conducted to assess the effect of ACTH on plasma VEGF levels.
    Summary · context
    Cosyntropin (a synthetic ACTH analogue) was administered at a low-dose (1 μg) given at t=0 minutes and a high-dose (250 μg) given at t=60 minutes.
  2. 02HumanNon-randomized trialMechanism

    In healthy children and adolescents, peak plasma VEGF did not significantly increase after low-dose cosyntropin versus baseline.

    In plain wordsIn healthy children and adolescents, low-dose cosyntropin did not significantly increase peak VEGF levels compared with baseline.

    Peptide
    Cosyntropin
    Outcome
    No significant changePeak plasma VEGF after low dose
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    1 μgAs given in this study (human).

    Source sentences

    Summary
    Peak plasma VEGF levels did not significantly increase after low-dose cosyntropin compared to baseline.
    2 context sentences
    Summary · context
    An Institutional Review Board-approved prospective study of 10 healthy subjects, ages 9-17, was conducted to assess the effect of ACTH on plasma VEGF levels.
    Summary · context
    Cosyntropin (a synthetic ACTH analogue) was administered at a low-dose (1 μg) given at t=0 minutes and a high-dose (250 μg) given at t=60 minutes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.